



Attorney Docket No. LeA 36 230

ORIGINAL

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Hendrix, et al.

Group No.:

Serial No.: 10/525,115

Examiner:


Filed: 18 February 2005

For: Phenyl-Substituted Pyrazolopyrimidines

**CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 11 April 2006

  
Gil Cunha

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed within three months of the filing or nationalization of this application, or before the mailing date of the first Office action on the merits.

**FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

  
Susan M. Pellegrino  
Attorney for Applicant(s)  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516

Reg. No.: 48,972

Telephone: (203) 812-6450

Date: 11 April 2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/525,115
		Filing Date	18 February 2005
		First Named Inventor	Hendrix, et al.
		Art Unit	
		Examiner Name	
Sheet 2	of 4	Attorney Docket Number	LeA 36 230

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	WEI, et al., Molecular and Pharmacological Analysis of Cyclic Nucleotide-Gated Channel Function in the Central Nervous System, Progress in Neurobiology, vol. 56, 1998, pp. 37-64	
	R2	FISHER, et al., Isolation and Characterization of PDE9A, A Novel Human cGMP-specific Phosphodiesterase, Journal of Biological Chemistry, vol. 273, no. 25, 1998, pp. 15559-15564	
	R3	GUIPPONI, et al., Identification and Characterization of a Novel Cyclic Nucleotide Phosphodiesterase Gene (PDE9A) That Maps to 21q22.3: Alternative Splicing of mRNA Transcripts, Genomic Structure and Sequence, Hum Genet, vol. 103, 1998, pp. 386-392	
	R4	SONDERLING, et al., Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry, vol. 273, no. 25, pp. 15553-15558	
	R5	ANDREEVA, et al., Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain, Journal of Neuroscience, vol. 21, no. 22, 2001, pp. 9068-9076	
	R6	MARTINS, et al., Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase from Bovine Tissues, Journal of Biological Chemistry, vol. 257, no. 4, 1982, pp. 1973-1979	
	R7	FRANCIS, et al. Characterization of a Novel cGMP Binding Protein from Rat Lung, Journal of Biological Chemistry, vol. 255, no. 2, 1980, pp. 620-626	
	R8	GILLESPIE, et al., Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cyclic GMP-Sepharose Chromatography, Journal of Biological Chemistry, vol. 263, no. 17, 1988, pp. 8133-8141	
	R9	FAWCETT, et al., Molecular Cloning and Characterization of a Distinct Human Phosphodiesterase Gene Family: PDE11A, Proc. Natl. Acad. Sci., vol. 97, no. 7, 2000, pp. 3702-3707	
	R10	MURASHIMA, et al., Characterization of Particulate Cyclic Nucleotide Phosphodiesterases from Bovine Brain: Purification of a Distinct cGMP-Stimulated Isoenzyme, Biochemistry, vol. 29, no. 22, 1990, pp. 5285-5292	

Examiner Signature	/Jeffrey Murray/	Date Considered	03/17/2008
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/525,115
		<b>Filing Date</b>	18 February 2005
		<b>First Named Inventor</b>	Hendrix, et al.
		<b>Art Unit</b>	
		<b>Examiner Name</b>	
<b>Sheet</b> 3	<b>of</b> 4	<b>Attorney Docket Number</b>	LeA 36 230

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R11	SODERLING, et al., Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions, Current Opinion in Cell Biology, vol. 12, 2000, pp. 174-179	
	R12	MIYASHITA, et al., Studies on Pyrazolo[3,4-d]Pyrimidine Derivatives. XVIII. Facile Preparation of 1H-Pyrazolo[3,4-d]Pyrimidin-4(5H)-Ones, Heterocycles, vol. 31, no. 7, 1990, p. 1309-1314	
	R13	SCHMIDT, et al., Helvetichechemische Studien in der Heterocyclischen Reihe 34. Mitteilung*) Pyrazolo-pyrimidine V*) Eine neue Synthese von Pyrazolo[3,4-d]Pyrimidinen mit coronareweiternden Eigenschaften, Helvetica Chimica Acta, no. 189, 1962, pp. 1620-1627	
	R14	LOUGHNEY, et al., Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3',5'-Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry, vol. 271, no. 2, 1996, pp. 796-806	
	R15	ROSMAN, et al., Isolation and Characterization of Human cDNAs encoding a cGMP-stimulated 3',5'-Cyclic Nucleotide Phosphodiesterase, Gene, vol. 191, 1997, pp. 89-95	
	R16	MIKI, et al., Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family, Genomics, vol. 36, 1996, pp. 476-485	
	R17	OBERNOLTE, et al., The cDNA of a Human Lymphocyte cyclic-AMP Phosphodiesterase (PDE IV) Reveals a Multigene Family, Gene, vol. 129, 1993 pp. 239-247	
	R18	LOUGHNEY, et al., Isolation and Characterization of cDNAs encoding PDE5A, a Human cGMP-Binding, cGMP-Specific 3',5'-Cyclic Nucleotide Phosphodiesterase, Gene, vol. 216, 1998, pp. 139-147	
	R19	HETMAN, et al., Cloning and Characterization of PDE7B, a cAMP-specific Phosphodiesterase, Proc. Natl. Acad. Sci., vol. 97, no. 1, 2000, pp. 472-476	
	R20	FISHER, et al., Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific Phosphodiesterase, Biochemical and Biophysical Research Communications, vol. 246, 1998, pp. 570-577	

<b>Examiner Signature</b>	/Jeffrey Murray/	<b>Date Considered</b>	03/17/2008
---------------------------	------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/525,115
		Filing Date	18 February 2005
		First Named Inventor	Hendrix, et al.
		Art Unit	
		Examiner Name	
Sheet 4	of 4	Attorney Docket Number	LeA 36 230

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R21	FUJISHIGE, et al., Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A), Journal of Biological Chemistry, vol. 274, no. 26, 1999, pp. 18438-18445	
	R22	HUETTNER, et al., Primary Culture of Identified Neurons from the Visual Cortex of Postnatal Rats, Journal of Neuroscience, vol. 6, 1986, pp. 3044-3060	

Examiner Signature	/Jeffrey Murray/	Date Considered	03/17/2008
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./